Keystone Financial Services Purchases New Stake in IQVIA Holdings Inc. $IQV

Keystone Financial Services acquired a new position in IQVIA Holdings Inc. (NYSE:IQV) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 1,298 shares of the medical research company’s stock, valued at approximately $205,000.

Several other hedge funds and other institutional investors have also modified their holdings of IQV. Clal Insurance Enterprises Holdings Ltd raised its stake in IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock worth $28,000 after acquiring an additional 131 shares during the period. AllSquare Wealth Management LLC bought a new position in shares of IQVIA during the first quarter valued at approximately $33,000. Trust Co. of Toledo NA OH acquired a new stake in shares of IQVIA during the 2nd quarter worth approximately $39,000. J.Safra Asset Management Corp boosted its position in IQVIA by 208.6% during the 2nd quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 169 shares during the period. Finally, NewSquare Capital LLC grew its stake in IQVIA by 185.3% during the 2nd quarter. NewSquare Capital LLC now owns 291 shares of the medical research company’s stock worth $46,000 after buying an additional 189 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. JPMorgan Chase & Co. boosted their price target on shares of IQVIA from $177.00 to $255.00 and gave the company an “overweight” rating in a report on Wednesday, October 29th. Truist Financial reissued a “buy” rating and set a $265.00 target price (up from $235.00) on shares of IQVIA in a research note on Wednesday, October 29th. Citigroup raised their price target on shares of IQVIA from $200.00 to $230.00 and gave the company a “neutral” rating in a research note on Wednesday, October 29th. Jefferies Financial Group upgraded IQVIA from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $195.00 to $225.00 in a research report on Tuesday, September 9th. Finally, Evercore ISI raised their target price on IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $239.94.

Insider Activity

In related news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the sale, the insider directly owned 27,108 shares in the company, valued at $5,955,627.60. The trade was a 12.86% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.60% of the stock is owned by corporate insiders.

IQVIA Stock Down 0.2%

Shares of IQV stock opened at $210.50 on Friday. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $225.00. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. The business’s fifty day moving average is $199.38 and its 200-day moving average is $176.07. The stock has a market cap of $35.85 billion, a PE ratio of 28.88, a price-to-earnings-growth ratio of 2.36 and a beta of 1.34.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, beating the consensus estimate of $2.98 by $0.02. The business had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The company’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter last year, the business posted $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Equities analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.